source
- City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debutCity Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…
- Biotech executive Steven Quay dropped from consideration for NIAID director roleSteven Quay, a biotech executive known for promoting the lab‑leak theory, was reportedly in the running to lead the National Institute for Allergy and Infectious Diseases. A source familiar with t…